The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma
Open Access
- 9 October 2015
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 138 (6) , 1528-1537
Abstract
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children. Despite multiple attempts at intensifying chemotherapeutic approaches to treatment, only moderate improvements in survival have been made for patients with advanced disease. Retinoic acid is a differentiation agent that has shown some antitumor efficacy in RMS cells in vitro; however, the effects are of low magnitude. E−3‐(4′‐hydroxyl‐3′‐adamantylbiphenyl‐4‐yl) acrylic acid (ST1926) is a novel orally available synthetic atypical retinoid, shown to have more potent activity than retinoic acid in several types of cancer cells. We used in vitro and in vivo models of RMS to explore the efficacy of ST1926 as a possible therapeutic agent in this sarcoma. We found that ST1926 reduced RMS cell viability in all tested alveolar (ARMS) and embryonal (ERMS) RMS cell lines, at readily achievable micromolar concentrations in mice. ST1926 induced an early DNA damage response (DDR), which led to increase in apoptosis, in addition to S‐phase cell cycle arrest and a reduction in protein levels of the cell cycle kinase CDK1. Effects were irrespective of TP53 mutational status. Interestingly, in ARMS cells, ST1926 treatment decreased PAX3‐FOXO1 fusion oncoprotein levels, and this suppression occurred at a post‐transcriptional level. In vivo, ST1926 was effective in inhibiting growth of ARMS and ERMS xenografts, and induced a prominent DDR. We conclude that ST1926 has preclinical efficacy against RMS, and should be further developed in this disease in clinical trials.Keywords
Funding Information
- Lebanese National Council for Scientific Research (CNRS)
- American Lebanese Syrian Associated Charities (ALSAC)
- International Outreach Program at St Jude Children's Research Hospital, Memphis, TN
- Children's Cancer Center of Lebanon
This publication has 46 references indexed in Scilit:
- New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasomeEuropean Journal of Cancer, 2013
- Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and PitfallsFrontiers in Oncology, 2013
- New Treatments for Rhabdomyosarcoma: The Importance of Target PracticeClinical Cancer Research, 2012
- Emerging roles for retinoids in regeneration and differentiation in normal and disease statesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Development and validation of a liquid chromatography–tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I studyJournal of Chromatography B, 2009
- KLF5 Promotes Breast Cell Survival Partially through Fibroblast Growth Factor-binding Protein 1-pERK-mediated Dual Specificity MKP-1 Protein Phosphorylation and StabilizationJournal of Biological Chemistry, 2009
- PAX3–FOXO1 fusion gene in rhabdomyosarcomaCancer Letters, 2008
- Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activityMolecular Cancer Therapeutics, 2008
- Response of human rhabdomyosarcoma cell lines to retinoic acid: Relationship with induction of differentiation and retinoic acid sensitivityExperimental Cell Research, 2005
- Rhabdomyosarcoma – working out the pathwaysOncogene, 1999